Dry Powder Inhaler Market Size, Share & Trends Growth [2031]

Report Description

The global dry powder inhaler market size was USD 19 Bn in 2022 and is likely to reach USD 29.6 Bn by 2031, expanding at a CAGR of 4.7% during 2023–2031. Increasing demand for several dry powder inhalers (DPIs) is likely to boost the market.

Rising number of individuals, especially, older kids and teens, suffering from chronic obstructive pulmonary disease and asthma disease is expected to boost the market.  The rise in deficiency of vitamin D in individuals, resulting from spending more time indoors, is playing a role in the increase in asthma cases. The prevalence of respiratory diseases is further increasing due to the lack of exercise, exposure to poor air quality, smoking, and overeating which, is expected to fuel the dry inhaler market. Companies in the market are developing and launching advanced DPI solutions, which are likely to expand the growth opportunities in the market.

• In September 2020, Teva Respiratory, LLC., a US affiliate of Teva Pharmaceutical Industries Ltd., launched two digital inhalers AirDuo Digihaler inhalation powder and ArmonAir Digihaler inhalation powder in the US. AirDuo Digihaler is used to control symptoms of asthma and to prevent symptoms such as breathlessness in individuals aged 12 years and older and ArmonAir Digihaler is a long-term treatment of asthma in patients in the similar age group.

Get Free Sample Report

DPI is easier to use and causes fewer irritant effects than MDI. DPIs deliver medication in a dry powder form, unlike MDIs, which use a propellant to deliver medication in a mist form. One of the most important advantages of DPIs is that they do not require coordination between inhalation and medication as MDIs do. This makes DPIs suitable for patients who have difficulty coordinating their breath with the inhaler.

The market report finds that the COVID-19 pandemic affected the market negatively, as patients with asthma are considered at increased risk of hospitalization from COVID-19 infection. Breathlessness is also a prevalent symptom among COVID-19 patients, which increased the demand for dry powder inhalers. The dry powder inhaler is expected to witness a significant demand growth in the coming years, due to the growing advancements in the device design and efficiency in the delivery of drugs through pulmonary pathways.

Dry Powder Inhaler Market Dynamics

Get Free Sample Report

Major Drivers

High demand for dry powder inhalers is expected to drive the market, owing to the benefits of powder in improving a person's condition, as pressure drops and increases inhaled flow rates. DPIs therapy is an effective method for treating respiratory diseases such as cystic fibrosis, asthma, and COPD. It is also been accepted and used in clinical practices. Post-COVID-19 pandemic there is increased interest in developing innovative solutions for breathing and infection issues which is triggering more potential applications of DPI therapy in antivirus drugs and vaccines.

• According to the National Center for Health Statistics, over 85 years of individuals visit physician ambulatory care for respiratory diseases and those between the age of 75 and 84 years have 57% and 85% lower rates.

Increasing advanced DPI technologies, as it is easier to use is expected to drive the market. DPIs are easier to use as compared to metered dose inhalers (MDI). A study found that around 80% of MDI users prefer using a DPI as it is easy to use. DPI often uses powdered lactose as an inactive ingredient. In developing countries, DPI has become a popular choice for patients, as it is easy to use and user-friendly.

Existing Restraints

High cost of asthma treatment is expected to hamper the dry powder inhaler market. An increasing number of patients are undergoing respiratory operations that require innovative inhalers, as they have chronic and obstructive respiratory disorders such as asthma and COPD. However, the high cost of inhaler devices for respiratory disorders can result in a decline in the adoption rate of inhalers. As a result, it can be challenging for low-income and middle-income countries to adopt such expensive equipment. This factor is expected to hinder the dry powder inhaler market.

Emerging Opportunities

High demand for personalized dry inhaler powder is expected to create lucrative opportunities for the market players. DPIs can deliver specific dosages and formulations, as per patient needs and medical conditions. Customized DPIs have their own identity, high IP protection, and are adaptable to API/formulation needs.

Scope of Dry Powder Inhaler Market Report

The market report includes an assessment of the market trends, market segments, and regional markets. Overview and dynamics have also been included in the report.

Dry Powder Inhaler Market Segment Insights

Type Segment Analysis

Based on type, the dry powder inhaler market is divided into single-dose DPIs and multi-dose DPIs. The single-dose DPIs segment is expected to expand at a significant pace during the projection period, due to the wider market penetration and a greater acceptability than other types. The single-dose DPIs are affordable and easy availability in developing countries which is likely to boost the segment in the market. Single-dose DPIs are used in separately packaged capsules that can drop into the chamber.

The multi-dose DPIs segment is anticipated to hold a key share of the market in the coming years, due to the increasing demand and utilization of dry powder inhalers. Multi-dose DPIs are preloaded with medication, which is typically prepared with a click of the device. It helps to improve patient adherence and compliance in the treatment of respiratory diseases such as COPD and asthma. Multi-dose DPIs are lightweight, easy to use, and suitable for all patient types.

• On January 30, 2023, Aptar Pharma launched APF Futurity, the first metal-free multidose nasal spray pump that provides nasal saline and other comparable over-the-counter formulations. It is the first recyclable nasal spray pump that received Class AA Certification from Cyclos HTP for recycling in Europe.

Application Segment Analysis

On the basis of application, the market is segregated into asthma, chronic obstructive pulmonary disease, cystic fibrosis, and others. The asthma segment is projected to register a considerable CAGR during the forecast period, due to the increase in asthma cases and rising air pollution levels. The DPI helps the medicine to get deep into the lungs, which makes it easier to breathe. DPI is easier to use as compared metered dose inhaler (MDI) and causes fewer irritant effects.

Get Free Sample Report

The chronic obstructive pulmonary disease (COPD) segment is anticipated to account for a major market share in the coming years. Chronic obstructive pulmonary disease dry powders can be used with a DPI including steroids such as bronchodilators and Pulmicort. It’s important to note that different types of inhalers work for different reasons. Some inhalers contain bronchodilators and some offer a combination of drugs.

• According to the American Lung Association, in the US, around 12.5 million people, or 5.0% of adults have reported a diagnosis of chronic obstructive pulmonary disease, emphysema, and chronic bronchitis in 2020.

Distribution Channel Segment Analysis

Based on the distribution channel, the dry powder inhaler market is segmented into hospital pharmacies, drug stores, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to register a robust growth rate during the forecast period. The increasing number of hospital pharmacies in emerging countries coupled with the rising number of dry powder inhaler prescriptions by hospitals is positively boosting the segment.

The online pharmacies segment is projected to hold a large market share in the coming years, due to the increasing number of retail e-commerce websites. Increasing consumer preference for online pharmacies to buy medicines and medical products is expected to boost the segment. With the availability of heavy discounts and the option of doorstep delivery, the segment is expected to grow at a considerable rate in the coming years.

Regional Analysis

In terms of region, the global dry powder inhaler market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period, due to the increasing number of patients with respiratory disorders and strict guidelines by regulatory authorities for medical devices. Increasing geriatric population and increased prevalence of asthma and other respiratory disorders in emerging countries such as the U.S. is anticipated to boost the market in the region.

The market in Europe is anticipated to expand at a rapid pace in the coming years, due to the increasing research & development activities to develop sustainable drugs and established healthcare infrastructure. The market is further attributed to the changes in lifestyle and the rise in asthma and illness among individuals.

• According to Asthma + Lung UK, around 12 million people in the UK, have been diagnosed with lung disease. There are around 550,000 new diagnoses of lungs each year. This is nearly around 80% higher than the number of diagnoses for non-respiratory cancers.

  Get Free Sample Report